Dosage for Tresiba (insulin degludec) depends on the type of diabetes (type 1 or type 2) it is prescribed for and other factors. Your doctor may adjust your dosage over the course of your ...

Behavioural difficulties and poor social skills are more common among children exposed to paternal depression, new research has underscored. Academics from Rutgers Health have found that children at ...

New data shows that more patients with type 2 diabetes achieved an average blood sugar level below 7% after using Novo Nordisk’s Victoza (liraglutide) for the first time, at any given time point ...

Whether you have a diagnosis or are curious about your options, this guide answers some of the most common questions about injectable medications for type 2 diabetes. Injectable medications ...

It has maintained its global diabetes value market share over the past year at 33.7%, fueled by Rybelsus, Ozempic and Victoza, putting up a strong performance. Novo Nordisk continues to be the ...

For example, research has shown that treatment with Ozempic, Trulicity, Rybelsus, or Victoza is linked to significant reduction in major heart problems, such as heart attacks, in people with ...

For example, spending for Ozempic increased from $0.4 billion to $26.4 billion, but combined spending on Victoza, Bydureon and Byetta decreased by $4 billion from $7.1 billion to $3.1 billion.

Women diagnosed with gestational diabetes during pregnancy are more likely to have children who go on to develop attention-deficient hyperactive disorder (ADHD), research has suggested. A new study ...

Albany, New York, April 17, 2025 (GLOBE NEWSWIRE) -- In thе last 30 yеars and thе Amеricas havе witnеssеd a significant surgе in adults diagnosеd with diabеtеs and attributеd to еscalatin ratеs of ...

Victoza (liraglutide) is a medication known to induce weight loss, although it lacks FDA approval specifically for this purpose; its FDA approval pertains to treating Type 2 diabetes. In 2020, the FDA ...

Lilly's drug proved itself equal to Victoza (liraglutide) in the study, a non-inferiority trial of once-weekly dulaglutide 1.5 mg versus a once-daily liraglutide 1.8 mg in reducing blood sugar levels.